The prefilled, patient-ready-to-use system is said to support delivery of high-viscosity biologics of up to 50 centipoise.

Becton Dickinson (BDX) recently announced the initiation of a pharma-sponsored clinical trial featuring their BD Libertas Wearable Injector, alongside an affirmed quarterly dividend and leadership ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable ...

Franklin Lakes, New Jersey Thursday, July 24, 2025, 14:00 Hrs [IST] ...

Becton Dickinson (BDX) announced the first pharma-sponsored combination product clinical trial using the BD Libertas Wearable Injector for ...

This year, three companies operating four plants in metro-Atlanta applied for an exemption to the new rule: Becton Dickinson ...

The selection of BD LibertasTM Wearable Injector for this pharma-sponsored trial follows successful outcomes from more than 50 BD-conducted pre-clini ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

In-Vitro Diagnostics Market 2025 IVD market set to grow at 5.0% CAGR to 2032, fueled by chronic disease demand, tech advances, and billion- ...

Plants in Cobb County and Covington have been the subject of lawsuits by cancer patients claiming the release of ethylene ...